Latest Advancements in Production of Therapeutic Antibodies in E. Coli

Sponsored by: Batavia Biosciences

Focused on:

  • Therapeutic Protein
  • Antibody Development
  • Biopharmaceutical Development
  • E Coli
  • Strain Development

Date: 12 December


Time: 3PM London/10AM New York

Showcase of a novel E. coli based fermentation technology

Microbial cells have been used for the production of therapeutic proteins since the late 70’s. E. coli is one of the preferred organisms since it is able to produce high yields in limited time with the use of cost-efficient medium and purification technology. The benefits of E. coli production resulted in the market launch of several blockbusting commercial recombinant therapeutic products like alpha-interferon, insulin or human growth factor to name a few.

However, microbes are less effective in post translational modifications, which is essential when it comes to complex protein structures like monoclonal antibodies. Driven by the increasing demand for fast and inexpensive production systems, especially for costly antibody therapies, two trends opened new opportunities to produce antibodies in E. coli; generation of improved engineered E. coli strains and new knowledge in using biologically functional antibody fragments. Based on this progression, ranibizumab and certolizumab pegol, two E. coli derived antibody fragments, have already been approved by the FDA and there are more to come.

This webinar will give you insights in the possibilities that E. coli fermentation systems can offer for manufacturing of therapeutic proteins, including antibody fragments. There will be special focus on our new fermentation technology: a system for a controlled regulation of protein expression yields in E. coli with a case study to showcase the latest technological advancements.

Want to learn how you can produce your next therapeutic antibody in a highly cost-efficient way, register now!

Presented by

Sagrario Arias Rivas,

Principal Scientist at Batavia Biosciences

Dr. Arias Rivas is Principal Scientist at Batavia Biosciences’ Project Office, where she is responsible for Innovation & Developing New Technologies. She has a profound background in Microbial Process Development for all major classes of biopharmaceuticals. Dr. Arias Rivas has a PhD on Molecular Biology and Biotechnology and is co-author of 5 patents and 16 scientific publications and book chapters.

For the past 10 years, she has hold positions at Batavia Biosciences, Helmholtz Centre for Infection Research and has worked on a collaborative project between Crucell Vaccine Institute and Leiden University. During this time, she has been involved in the development of several vaccines and the production of (therapeutic) proteins, antibodies and biopolymers.

Key Learning Objectives

  • Learn the pros and cons of microbial production platforms for biopharmaceuticals
  • How to optimize your E. coli strain generation
  • How to increase your translational success rate


  • Biopharmaceutical Heads of R&D
  • Head of Technical Operations
  • R&D Project Managers
  • CSO in Biopharmaceutical Start-up Organisations
  • CEO in Biopharmaceutical Start Up Organisation
  • Academics working in Biopharmaceutical grants
  • Consultants in Biopharmaceutical Process Development